Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -1.69117647059 | 13.6 | 13.8016 | 12.31 | 691242 | 13.10855923 | CS |
4 | 0.76 | 6.02696272799 | 12.61 | 16.17 | 12.31 | 1124767 | 13.81902936 | CS |
12 | -8.22 | -38.0731820287 | 21.59 | 22.9 | 12.25 | 1264655 | 16.12866404 | CS |
26 | 8.56 | 177.962577963 | 4.81 | 23.4 | 3.52 | 2016638 | 14.02233359 | CS |
52 | 9.23 | 222.946859903 | 4.14 | 23.4 | 3.52 | 1194842 | 12.71952078 | CS |
156 | 10.32 | 338.360655738 | 3.05 | 23.4 | 2.56 | 522032 | 10.75591295 | CS |
260 | 11.58 | 646.927374302 | 1.79 | 23.4 | 0.88 | 927590 | 7.73953738 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約